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Mohammad Kamalinejad6 and Ali Ghobadi7Abstract
Background: Tribulus terrestris as a herbal remedy has shown beneficial aphrodisiac effects in a number of animal
and human experiments. This study was designed as a randomized double-blind placebo-controlled trial to assess
the safety and efficacy of Tribulus terrestris in women with hypoactive sexual desire disorder during their fertile
years. Sixty seven women with hypoactive sexual desire disorder were randomly assigned to Tribulus terrestris extract
(7.5 mg/day) or placebo for 4 weeks. Desire, arousal, lubrication, orgasm, satisfaction, and pain were measured at
baseline and after 4 weeks after the end of the treatment by using the Female Sexual Function Index (FSFI). Two
groups were compared by repeated measurement ANOVA test.
Results: Thirty women in placebo group and thirty women in drug group completed the study. At the end of the
fourth week, patients in the Tribulus terrestris group had experienced significant improvement in their total FSFI
(p < 0.001), desire (p < 0.001), arousal (p = 0.037), lubrication (p < 0.001), satisfaction (p < 0.001) and pain (p = 0.041)
domains of FSFI. Frequency of side effects was similar between the two groups.
Conclusions: Tribulus terrestris may safely and effectively improve desire in women with hypoactive sexual desire
disorder. Further investigation of Tribulus terrestris in women is warranted.
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Hypoactive sexual desire disorder (HSDD) is a multi fac-
torial and multifaceted disorder which has been entangled
with biologic and psychological considerations and inter-
personal relations. HSDD is a common sexual complaint
affecting approximately 1 in 10 adult women in the USA
[1,2], and its prevalence appears to be similar in Europe
(7%-16%) [3] and Australia (16%) [4]. According to some
scientific reports the prevalence in Iran is 30% [5].
Currently there are two therapeutic modalities for
women who suffer from the lack of libido: psychotherapy
and pharmacotherapy. Several drugs have been suggested* Correspondence: Fraisi@gmail.com
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unless otherwise stated.for treating women’s loss of libido including estrogen, me-
thyl testosterone [4], phenethylamin [5], bupropion [6]
and saffron [7]. However, there is no Food and Drug Ad-
ministration (FDA) approved drug for treating women’s
HSDD [8,9].
Avicenna’s The Canon of Medicine (1025 AD) provides
a full chapter to the description of libido, its disorders
and treatments. Twentieth chapter of the book discusses
the libido under rubric of “Bah”, its disorders and causes
that may boost and reduce the sex drive as well as treat-
ments for each cause [10]. According to the Canon of
Medicine and Aghili Khorasani’s Makhzan al-Advia (The
treasury of Spices) (18th AD), Bindii or Tribulus terrestris
influences libido [11] and is able to boost sex drive in hu-
man beings. According to the Iranian Traditional Medi-
cine (ITM) deregulation and disorders of libido in both
sexes is considerably common. It is worthy to mention
that, ITM is based on principles of Humorist school andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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but the mentioned herbal medicine, Tribulus terrestris,
has been classified as an experimental remedy because it
affects all four humors and boosts the libido.
Recent scientific studies on medicinal herbs have referred
to Tribulus terrestris as an effective drug of women’s sex
drive [12]. A study on mice hypothesized that the drug may
affect follicle-stimulating hormone (FSH) and luteinizing
hormone (LH); injecting 10 mg of Tribulus extract into
female mice resulted in significant increase in both
growth rate and size of follicles in comparison to the
control mice [13].
The aim of our clinical trial was to analyze the effect
of Tribulus on women with HSDD in childbearing age.Methods
Trial design
This was a randomized, double-blind, placebo-controlled
clinical trial study, performed in two medical centers
in Tehran Province, Rostamabad Neighborhood Health
Center, part of the 1st district of the greater Tehran
Municipality, and Sajjad Hospital in city of Shahryar.
This study was approved by the ethics committee of
School of Medicine, Tehran University of Medical Sciences
(TUMS), and it was registered in the clinical trial center
under reg. no. of IRCT20121111111425N1Participants
Participants of the study were selected after responding
to this specific question “Do you suffer from loss of libido?”
in a direct and face to face encounter, and the study was
conducted from June 2012 to July 2013. Then a phone
interview was scheduled for all 96 women who were se-
lected; and subsequently they were invited for a screening
visit after verification of their disorder. The inclusion cri-
teria of the study were: being married and actively living
with a partner at least 15 days per month, being in child-
bearing age, lack and or loss of libido which causes dis-
tress, having normal pelvic exam, negative pap smear test
conducted at least within past six months, and having
normal breast exam. The exclusion criteria were: lack of
steady sexual partner, suffering from a serious medical
condition (any disease which may force the participant
to use drugs during the study), any history of genital
tract or breast cancers, suffering from major depression
disorder or other psychiatric disorders, menopause, preg-
nancy, husband’s sexual problems and active plans for
divorce. Participants with the mentioned inclusion cri-
teria were allowed to start the next stage which was a
face to face interview based on Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-IV-TR) codes
for HSDD [14]. Finally patients were asked to sign the
informed consent forms.Preparations of tribulus terrestris
Tribulus is widely scattered across the planet a herbal
plant [15]. Tribulus belongs to Zygophyllaceae family.
Alpha amyrin constitutes over 60% of active ingredient
(AI) of the herb [16]. Dried leaves of Tribulus were ob-
tained from a licensed distributer of herbs and natural
remedies in Tehran. They were approved and registered
by the SHUM herbarium (voucher number: SHUM 8051).
Preparations of syrup and placebo
Traditional Medicine Department, School of Medicine,
TUMS used the whole vaporized ethanolic extract of
Tribulus terrestris for preparing the syrup. There was
3.5 grams of ethanolic extract in every 5 ml of the syrup.
The placebo was prepared via the same method without
Tribulus terrestris extract as a sucrose syrup.
Treatment and assessment
Each participant was initially asked to fill the Female Sex-
ual Function Index (FSFI) (21) a self-reported question-
naire under supervision of an Iranian traditional medicine
intern who was already trained by a gynecologist and a
psychiatrist for conducting the trial, and then she was pro-
vided with a drug bottle with specific coding. Drug Product
Information Form (DPIF) was inscribed on a label attached
to the bottle. The specific code was recorded on both ques-
tionnaire and participant’s data sheet. The DPIF instruc-
tions included this information: 7.5 ml of the drug should
be used two times a day for four full weeks since the day
after the completion of menstruation period. Two days
after submitting the drug, the patient was checked by a
physician through a phone call in order to make sure that
the drug was used correctly. Again, after a week a second
phone call was made to make sure of continuity of the
mentioned order. Patients, who forgot to use more than
three doses of their drugs, were excluded. Another inter-
view according to the DSM-IV-TR criteria for HSDD was
made four weeks after completion of the drug therapy, side
effects (if any) were checked and FSFI questionnaire was
refilled. The participants were allowed to call their therap-
ist during the treatment period.
Outcomes
The participants filled the FSFI questionnaire [1,17] two
times: 1) at the beginning of the study, 2) four weeks
after finishing their drug. The questionnaire have 19 ques-
tions with six domains included desire, arousal, lubrication,
orgasm, satisfaction and pain, and a general score in which
higher scores reflected better sexual activity. Questions 1
and 2 were related to the sexual desire and its score varied
between 1.2 and 6. Questions 3, 4, 5 and 6 analyzed arousal
of the patient. Another domain of the questionnaire was
lubrication which covered questions 7, 8, 9, and 10. The or-
gasm domain included questions 11, 12 and 13. Questions
Akhtari et al. DARU Journal of Pharmaceutical Sciences 2014, 22:40 Page 3 of 6
http://www.darujps.com/content/22/1/4014, 15 and 16 all were related to the sexual satisfaction and
finally questions 17, 18 and 19 analyzed pain.
The initial outcome was the assessment of desire and
total score of our samples with FSFI before and after inter-
vention. Likewise, different subscales including arousal, lu-
brication, orgasm, satisfaction and pain were compared as
the secondary targets using the questionnaire before and
after treatment. The FSFI question contained 19 questions
which analyzed five domains of women’s sexual function.
Side effects were recorded systematically within the trial
period through visits made within 1, 2 and 4 weeks and
after the end of pharmacotherapy.
Sample size
The statistical power was set at 80% in order to achieve
a minimum score of 3, to improve the “sexual desire”
score in the intervention (experimental) group in com-
parison with the control group. The standard deviation
(SD) was 3.5 (resulted from our pilot study). In regards to
possibility of loss measuring 20% during the study period,
we achieved significance level of 95% and a bilateral t-test.
Randomization, allocation concealment, and blinding
The randomized sequence was produced by a method-
ology using randomization permuted block technique
with blocks size of 4 which was submitted to therapists
with ratio 1:1 divided in two groups. The randomized se-
quence for allocating the main or placebo treatment was
concealed through producing unknown codes; hence, pre-
provided drugs and placebo were submitted through
similar packs but different codes, as neither therapists
nor patients were aware of the active ingredient of the
drug packs.
Statistical analysis
Descriptive baseline characteristics for two groups com-
parisons were tabulated as means and SD or as percent-
ages. All analyses comparing the efficacy of our primary
and secondary outcomes were by intention-to-treat prin-
ciples. Using General Linear Model (GLM) score of de-
sire, arousal, lubrication, orgasm, satisfaction, and pain
between two groups were compared by repeated measure-
ment ANOVA test. Compound symmetry assumption was
tested using Mauchley’s Sphericity test. The time groups
cross-product (interaction term) was considered as group
differences in their response over time with the baseline
values as a covariate in this model. Significance level of 5%
(alpha = 0.05) was used for all statistical tests.
Results
A total of 96 women were enrolled for the study (Figure 1),
and 67 women were identified as qualified (out which two
women decided not to participate after acquiring DSM IV
codes and upon issuing the informed consent, three otherwomen stopped participating at the second phone call
time point despite receiving drug and answering the first
phone call. According to the code recorded on the ques-
tionnaire, (before taking drug) it was turned out that two
women were from the placebo group and another one was
from the drug group. Their reasons for stopping partici-
pating at the studying included very sweet taste of the
drug (one woman) and anxiety due to using an investiga-
tional drug (two women). Another two women were not
available after getting off the study; they signed the con-
sent form, but there was no drug available at that time
when they were in the center, and they never came back
to receive their ration. Between June 2012 and July 2013,
participants took part in an interview and then they filled
the FSFI questionnaire; then they were assigned randomly
in drug and placebo groups. There was a second visit a
week after starting pharmacotherapy and third visit was
made four weeks after termination of the treatment which
was accompanied with the filling of the questionnaire for
the second time. Hence patients in average were followed
up for two consecutive months (Figure 1).
60 women out of 67 participants completed their treat-
ment process and the results were analyzed according to
what was recorded in their questionnaires. The mean ages
of drug and control groups were 36 ± 6.24 years and
36.13 ± 5.88 years, respectively. 70% and 66.6% of partici-
pants in drug and control groups had bachelor or higher
educational degrees (Table 1). 30 members of Tribulus
and 30 members of the placebo group completed their
treatment process.
Patients’ desire was the main measured outcome of
the study in both groups (Table 2) which was measured
after four weeks of pharmacotherapy process by using
the Female Sexual Function Index (FSFI) questionnaire
and the following scores were gained: score of placebo
group, before and after intervention, respectively: 2.66 ±
0.75 and 2.86 ± 0.79; scores of Tribulus group, before and
after intervention, respectively: 3.06 ± 0.69 and 3.90 ± 0.71.
After matching the effect of the possible effective vari-
ables (age, pregnancy rate, method of delivery, method
of contraception), the difference became significant sta-
tistically (p < 0.001).
Another variable analyzed in this study was arousal
which was measured four weeks after completion of the
treatment process through the FSFI questionnaire. Scores
of placebo group before and after pharmacotherapy were
3.16 ± 0.95 and 3.17 ± 0.75; Scores of intervention group
before and after using Tribulus terrestris were 3.61 ± 0.92
and 4.21 ± 0.67. After matching the effect of the possible
effective variables (age, pregnancy rate, method of delivery,
method of contraception), the difference became signifi-
cant statistically (p = 0.037).
According to the FSFI another secondary variable was
lubrication. Similar to two previous variables lubrication
96 patients screened 
Not meeting inclusion criteria: 17 
Meeting exclusion criteria: 5 
Refused to participate: 7 
Randomized: 67
33 assigned for drug 34 assigned for placebo
3 discontinued at baseline 4 discontinued at baseline
30 completed trial 30 completed trial 
Figure 1 Flow chart indicating subject enrolment, group allocation and analysis according to CONSORT guidelines.
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ment. Scores of this domain gained by placebo group be-
fore and after usage were 4.15 ± 1.15 and 4.18 ± 0.79 while
scores won by intervention group were 4.15 ± 1.13 and
4.66 ± 0.87. After matching the effect of the possible ef-
fective variables (age, pregnancy rate, method of delivery,
method of contraception), the difference became signifi-
cant statistically (p < 0.001).
Orgasm was analyzed using the FSFI questionnaire
after four weeks of completion of treatment with Tribulus
terrestris. Scores of this domain gained by placebo groupTable 1 Demographic and baseline characteristics of patients
Age (years), mean ± SD



















mean ± SDbefore and after usage were 3.31 ± 0.97 and 3.59 ± 0.85
while scores won by intervention group were 3.21 ± 0.98
and 4.20 ± 0.72. After matching the effect of the possible
effective variables (age, pregnancy rate, method of deliv-
ery, method of contraception), the difference became sig-
nificant statistically (p < 0.001).
Satisfaction was measured four weeks after completion
of treatment process through the FSFI questionnaire.
Scores of this domain gained by placebo group before
and after pharmacotherapy were 3.43 ± 1.13 and 3.75 ±
1.12; scores won by intervention group before and afterTribulus (n = 30) Placebo (n = 30)
36 ± 6.24 36.13 ± 5.88
39.87 ± 7.13 40.43 ± 7.74













14 ± 5.97 12.73 ± 6.22
Table 2 Summary results for each study group
Mean differences Placebo Tribulus terrestris
(CI 95%) N = 30 N = 30
Control Baseline Control Baseline
Mean ± SD Mean ± SD mean ± SD mean ± SD
Desire 3.66 ± 0.69 3.90 ± 0.71 2.66 ± 0.75 2.86 ± 0.79 0.71 (0.41 – 1.01) p < 0.001
Arousal 3.61 ± 0.92 4.21 ± 0.67 3.16 ± 0.95 3.17 ± 0.75 0.75 (0.47 – 1.46) p = 0.037
Lubrication 4.15 ± 1.13 4.66 ± 0.87 4.15 ± 1.15 4.18 ± 0.79 0.50 (0.32 – 0.68) p < 0.001
Orgasm 3.21 ± 0.98 4.20 ± 0.72 3.31 ± 0.97 3.59 ± 0.85 0.85 (0.56 – 1.14) p < 0.001
Satisfaction 3.44 ± 1.15 4.61 ± 0.93 3.43 ± 1.13 3.75 ± 1.12 1.10 (0.73– 1.48) p < 0.001
Pain 4.19 ± 1.56 5.07 ± 1.01 4.19 ± 1.51 4.87 ± 1.42 0.37 (0.16 – 0.73) p < 0.001
General score 22.41 ± 2.87 26.80 ± 3.03 20.39 ± 4.64 21.25 ± 4.72 4.32 (3.33 – 5.31) p = 0.040
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After matching the effect of the possible effective vari-
ables (age, pregnancy rate, method of delivery, method
of contraception), the difference became significant sta-
tistically (p < 0.001).
Pain was measured four weeks after completion of treat-
ment process through the FSFI questionnaire. Scores of
this domain gained by placebo group before and after
pharmacotherapy were 4.19 ± 1.51 and 4.87 ± 1.42; scores
won by intervention group before and after using Tribulus
terrestris were 4.19 ± 1.56 and 5.07 ± 1.01. After matching
the effect of the possible effective variables (age, preg-
nancy rate, method of delivery, method of contraception),
the difference became significant statistically (p = 0.041).
Finally general scores of both drug and placebo groups
were analyzed and compared based on FSFI questionnaire
four weeks after completion of intervention. The general
scores in placebo and intervention groups before using
Tribulus terrestris were 20.89 ± 6.46 and 21.25 ± 4.72,
respectively; and four weeks after its completion were
22.41 ± 2.87 and 26.80 ± 3.03, respectively (p = 0.040). These
results confirmed by the interviews using DSM-IV-TR
(Table 2).
Safety assessment
Possible side effects including abdominal pain, cramping,
nausea, vomiting, diarrhea or constipation were recorded
using Common Terminology Criteria for Adverse Events
(CTCAE) Version 4.02 during the scheduled visits. Only
one patient reported grade 1 abdominal cramp.
Discussion
Our findings showed that Tribulus terrestris was effect-
ive in improving women’s sex drive based on the ques-
tions of FSFI questionnaire. Since the basic findings of
two groups were similar, the improved score of the Tri-
bulus group can be attributed to libido boosting effects
of the plant. Our findings confirmed what has already been
described in the Iranian Traditional Medical textbooksabout libido boosting effects of Tribulus. There is also
more recent evidence that Tribulus can be used as a libido
booster plant in women [12]. There may be a possible syn-
ergy between Tribulus and FSH-LH mechanism. For in-
stance, one animal experiment showed that mice, injected
with 10 mg Tribulus extract, developed thicker theca in-
ternal layer and more follicles in comparison with control
mice in the same period of time [13].
Prescribing Tribulus extract for women can increase
desire score in women who suffer from loss of sex de-
sire. However, according to our knowledge there has not
been any similar research on the impact of Tribulus ex-
tract in improving women’s sex desire in childbearing age.
The effect of testosterone in improving desire in meno-
pausal women has been confirmed by studies that have
looked at women’s sex drive and how to boost it [18,19].
The role of conjugated testosterone in treating lack of sex
drive has been emphasized [20]. Currently testosterone
is the only approved drug for treatment of HSDD in
menopausal women, particularly for those have surgically-
induced menopause [21]. In one study on women with
SSRI induced desire disorder, it was shown that Saffron
was an effective herbal remedy which could improve de-
sire [7]. Another study showed that Bupropion was effect-
ive in improving women’s desire [6]. However, Tribulus is
the only drug which not only improves the sexual desire
in women but also it does not have any unexpected side
effects in patients.
Our study showed very clearly through acquired scores
of the FSFI questionnaire that patients had significant
increase in their scores related to questions about desire,
arousal and satisfaction. Our results indicated a consid-
erable improvement in scores of desire. Thus, Tribulus
had apparent boosting effects on desire, and it was able
to improve sexual satisfaction and sexual behavior.
Although our study showed the effect of Tribulus on
improving the desire, it must be noticed that Iranian
women are generally modest and shy because of their cul-
tural beliefs about sexual concepts, and our sample size
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more reliable evidence, more studies with a large sample
size must be carried out.
Conclusion
Tribulus terrestris may safely and effectively improve
desire in women with HSDD. Further investigation of
Tribulus terrestris in women is warranted.
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